Qualitative Analysis of Interviews Between Pharmacist and Elderly Patients Treated with Antithrombotics for an Ischemic Stroke.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Analysis of the verbatim from the transcription of the recorded interviews..
- Who it may be relevant to
- Registry conditions: Stroke. Basic parameters: 65 years — 100 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. There are brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.
Detailed description
Cerebrovascular accident is the 2nd leading cause of death and the leading cause of disability in the world. The probability of stroke recurrence is high: about 25% the first year , and 30 to 40% in the 5 years following the stroke. Recurrent strokes are responsible for significant disability, institutionalization, major neurocognitive disorders, and death.
In order to reduce the risk of stroke recurrence, multiple secondary prevention strategies have demonstrated their effectiveness, such as the prescription of drugs (in particular statins and antithrombotics), the establishment of a balanced diet, the practice of an activity physical, or even tobacco addiction.
However, the effectiveness of these strategies is optimal if and only if patients adhere to them.
In addition, previous studies have focused on the brakes and levers of medication adherence in the context of secondary prevention treatment in stroke.
In elderly patients, other obstacles could have been identified by specific studies, such as cognitive, sensory, functional disorders or even isolation.
Interventions
- Other Analysis of the verbatim from the transcription of the recorded interviews.
recorded semi-structured interviews between the patients and the pharmacist
Primary outcome measures
- Analysis of the verbatim from the transcription of the recorded interviews. [Time frame: one year]
Secondary outcome measures (4)
- Analysis of verbatim statements from the transcription of recorded interviews on patients' representations and beliefs regarding antithrombotics [Time frame: 15 to 60 minutes per patient]
- Analysis of verbatim statements from the transcription of recorded interviews on patients' medication adherence to antithrombotics [Time frame: 15 to 60 minutes per patient]
- Analysis of verbatim statements from the transcription of recorded interviews on the impact of the occurrence of stroke or recurrence of stroke on medication adherence [Time frame: 15 to 60 minutes per patient]
- Analysis of verbatim statements from the transcription of recorded interviews on the obstacles and levers to medication adherence [Time frame: 15 to 60 minutes per patient]
Eligibility criteria
Inclusion criteria
- Patients aged 65 and over
- Patients hospitalized for an ischemic stroke or a recurrence of ischemic stroke, already being treated with an antithrombotic treatment (antiplatelet agent or anticoagulant ) prior to the stroke
- Patients living at home and with a plan to return home.
- Patients who did not object to the study and who gave their consent for the recording of the interview
Exclusion criteria
- Patients with cognitive disorders or stroke sequelae that do not allow a semi-directive interview to be carried out (at medical discretion).
- Non-French speaking patients
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
France · 1 center
- institute of aging - Hôpital des Charpennes — Villeurbanne
Identifiers
NCT: NCT05741593 · 69HCL22_1074 · 2023-A00181-44